Your chance
to interpret clinical endpoints the same way the FDA interprets them!
Switch the sound ON so you can start learning!
For the FDA to approve new cancer medications, the FDA uses endpoints as a tool to prove these medications are effective and worth using for our patients. In the video, you will learn about the commonly used endpoints in oncology trials.
Hematology Oncology Fellow
Karmanos Cancer Institution
Wayne State University, Detroit, MI, USA
References:
1. Clinical Trial Endpoints for the Approval of Cancer Drugs and Biologics. FDA website (https://www.fda.gov). Accessed Oct 2021
2. Gill S, Berry S, Biagi J, et al. Progression-free survival as a primary endpoint in clinical trials of metastatic colorectal cancer. Curr Oncol. 2011;18 Suppl 2(Suppl 2):S5-S10.
3. Spruance SL, Reid JE, Grace M, Samore M. Hazard ratio in clinical trials. Antimicrob Agents Chemother. 2004;48(8):2787-2792. doi:10.1128/AAC.48.8.2787-2792.2004
4. New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1) by J. Verweijk
5. Barraclough H, Simms L, Govindan R. Biostatistics primer: what a clinician ought to know: hazard ratios. J Thorac Oncol. 2011 Jun;6(6):978-82. doi: 10.1097/JTO.0b013e31821b10ab. Erratum in: J Thorac Oncol. 2011 Aug;6(8):1454. PMID: 21623277
6. Hsu CY, Lin EP, Shyr Y. Development and Evaluation of a Method to Correct Misinterpretation of Clinical Trial Results With Long-term Survival. JAMA Oncol. 2021 Jul 1;7(7):1041-1044. doi: 10.1001/jamaoncol.2021.0289. PMID: 33856410; PMCID: PMC8050786.
7. Visuals and figures were created with BioRender.com